These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Author: Lee H, Kim SK, Kim YI, Kim TS, Kang SH, Park WS, Yun T, Eom HS.
    Journal: J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650.
    Abstract:
    UNLABELLED: PET is a potentially useful modality for response analysis and prognosis prediction in patients with high-grade non-Hodgkin lymphoma (NHL). The thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) was recently introduced as a new tracer. (18)F-FLT uptake correlates with tumor cell proliferation and is suggested to reflect early response to treatment. We performed a prospective study to evaluate the prognostic value of early interim (18)F-FLT PET in patients with NHL. METHODS: Patients with untreated NHL were enrolled between 2005 and 2007. Among them, 61 pairs of (18)F-FLT PET images were obtained at baseline (pre), after 1 cycle of chemotherapy (interim), and at the end of all scheduled first-line chemotherapy (final). All (18)F-FLT PET scans were interpreted by quantitative methods (maximum standardized uptake value [SUV max] and mean standardized uptake value [SUV mean]). Receiver-operating-characteristic curve analysis was performed to define (18)F-FLT PET positivity using a cutoff value predicting disease progression, relapse, or death. Survival outcome was measured by progression-free survival (PFS) and overall survival (OS) rates. RESULTS: Receiver-operating-characteristic curve analysis of SUV max for prediction of disease progression and death showed the highest area under the curve (AUC) in interim (18)F-FLT PET scans (AUC of 0.841 for PFS and 0.834 for OS, with a cutoff of 1.86; P < 0.001), compared with pre and final (18)F-FLT PET scans. The SUV mean in interim (18)F-FLT PET scans also showed better prediction (AUC of 0.842 for PFS and 0.824 for OS, with a cutoff value of 1.65; P < 0.001) than pre and final (18)F-FLT PET scans. Patients with an interim (18)F-FLT PET SUV max more than 1.86, who were defined as the interim PET-positive group, were associated with worse 5-y PFS and OS rates than the interim PET-negative group (for PFS: 52.0% vs. 80.7%, respectively, and P < 0.001; for OS: 56.2% vs. 81.4%, respectively, and P < 0.001). By multivariable analysis, the prognostic value of interim (18)F-FLT PET positivity by SUV max remained significant after adjustment with other prognostic factors (for PFS: hazard ratio, 7.82, 95% confidence interval, 1.65-36.96, and P = 0.009; for OS: hazard ratio, 5.55, 95% confidence interval, 1.47-33.77, and P = 0.014). CONCLUSION: In patients with aggressive NHL, early interim (18)F-FLT PET is a significant predictor of PFS and OS. Early (18)F-FLT PET imaging also has a potential to identify patients with delayed response and nonfavorable prognosis despite achieving a clinical complete response.
    [Abstract] [Full Text] [Related] [New Search]